The project involves participatory decision-making (PEF) with stage II/III melanoma patients regarding the use of adjuvant systemic therapy (immunotherapy, targeted therapy), as well as identifying unjustified variations in treatment uptake. PEF is intended to reduce decision-making conflicts and to determine the target utilization rates following optimal patient involvement (PEF).
The study examines whether certain measures help ensure that patients' needs are given greater consideration in treatment decisions.
